Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
In brief
Pyxis Oncology’s stock climbed after naming a CEO with a strong deal‑making background and gearing up to unveil promising clinical data, sparking short‑term upside and potential long‑term partnership opportunities.